Patents by Inventor Javier Guenaga

Javier Guenaga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multispecific Anti-HIV Antibodies
    Publication number: 20220227845
    Abstract: The present invention provides a multispecific anti-HIV antibody that binds to multiple epitopes on HIV envelope protein, wherein the antibody comprises: i. an amino acid sequence that binds to a V1/V2 apex glycan epitope; ii. an amino acid sequence that binds to a V3-base glycan region epitope; iii. an amino acid sequence that binds to a CD4 binding site (CD4bs) epitope; iv. an amino acid sequence that binds to a gp120/gp41 interface epitope; and v. an amino acid sequence that binds to a membrane proximal external region (MPER) epitope.
    Type: Application
    Filed: October 18, 2019
    Publication date: July 21, 2022
    Inventors: Yuxing Li, James Steinhardt, Javier Guenaga, John R. Mascola, Tae-Wook Chun, Susan Moir, Chi-I Chiang
  • Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
    Patent number: 11149082
    Abstract: The present disclosure relates to multispecific antibodies targeting the human immunodeficiency virus-1 (HIV-1) envelope, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof in treatment and prevention of HIV infection.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: October 19, 2021
    Assignees: University of Maryland, College Park, The United States of America, As Represented By, International AIDS Vaccine Initiative
    Inventors: Javier Guenaga, Yuxing Li, James Steinhardt, John R. Mascola
  • N-glycan deleted HIV-1 envelope glycoprotein trimers
    Patent number: 10870683
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: December 22, 2020
    Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Viktoriya Dubrovskaya, Francisco Javier Guenaga, Richard Wyatt
  • MULTISPECIFIC ANTIBODIES TARGETING HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USING THE SAME
    Publication number: 20200123236
    Abstract: The present disclosure relates to multispecific antibodies targeting the human immunodeficiency virus-1 (HIV-1) envelope, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof in treatment and prevention of HIV infection.
    Type: Application
    Filed: October 17, 2017
    Publication date: April 23, 2020
    Inventors: Javier Guenaga, Yuxing Li, James Steinhardt, John R. Mascola
  • N-GLYCAN DELETED HIV-1 ENVELOPE GLYCOPROTEIN TRIMERS
    Publication number: 20190135872
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Application
    Filed: September 13, 2018
    Publication date: May 9, 2019
    Inventors: Viktoriya Dubrovskaya, Francisco Javier Guenaga, Richard Wyatt
  • Soluble HIV-1 envelope glycoprotein trimers
    Patent number: 10174292
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: January 8, 2019
    Assignees: International AIDS Vaccine Initiative, The Scripps Research Institute
    Inventors: Viktoriya Dubrovskaya, Francisco Javier Guenaga, Richard Wyatt
  • Soluble HIV-1 envelope glycoprotein trimers
    Patent number: 10058604
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: August 28, 2018
    Assignees: International AIDS Vaccine Initiative, The Scripps Research Institute
    Inventors: Richard Wyatt, Andrew Ward, Karen Tran, Shailendra Kumar, Jidnyasa Ingale, Javier Guenaga, Yu Feng, Viktoriya Dubrovskaya, Natalia de Val Alda
  • SOLUBLE HIV-1 ENVELOPE GLYCOPROTEIN TRIMERS
    Publication number: 20170035877
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Application
    Filed: October 7, 2014
    Publication date: February 9, 2017
    Inventors: Richard Wyatt, Andrew Ward, Karen Tran, Shailendra Kumar, Jidnyasa Ingale, Javier Guenaga, Yu Feng, Viktoria Dubrowskaya, Natalia de Val Alta
  • SOLUBLE HIV-1 ENVELOPE GLYCOPROTEIN TRIMERS
    Publication number: 20160272948
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Application
    Filed: March 21, 2016
    Publication date: September 22, 2016
    Inventors: Viktoriya Dubrovskaya, Francisco Javier Guenaga, Richard Wyatt
  • MAMMALIAN PROTEIN CO-RECOGNITION BY BROADLY NEUTRALIZING ANTIBODIES AS MODIFIED IMMUNOGENS FOR RE-ELICITATION
    Publication number: 20160033532
    Abstract: The present invention relates to using HIV-1 broadly neutralizing antibodies to screen for glycan-dependent or protein-dependent self reactivities inherent in these mutated antibodies, and defining this cross recognition at the molecular level, and utilizing the information to re-elicit trimer-specific and/or N-glycan-dependent or protein-surface-dependent broadly neutralizing antibodies and therapeutic applications thereof.
    Type: Application
    Filed: July 30, 2015
    Publication date: February 4, 2016
    Inventors: Richard Wyatt, Karen Tran, Javier Guenaga, Shailendra Kumar
  • EPITOPE-TRANSPLANT SCAFFOLDS AND THEIR USE
    Publication number: 20100068217
    Abstract: Computational protocols for the design of epitope-protein scaffolds which elicit selected neutralizing antibodies are disclosed, and related compositions and uses.
    Type: Application
    Filed: August 24, 2007
    Publication date: March 18, 2010
    Inventors: Peter D. Kwong, Gilad Ofek, Javier Guenaga, Richard Wyatt, Zhi-yong Yang, Tongqing Zhou, Gary J Nabel, Min Tang, William Schief, David Baker